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The treatment of obstructive sleep apnea (OSA) allows for a multidisciplinary approach
between dentistry and medicine. Continuous positive airway pressure (CPAP) is the gold standard
for OSA treatment, but the non-adherence rates are high. The mandibular advancement device
(MAD) has a higher acceptance rate than the CPAP, however the efficacy is much lower in cases
of moderate to severe OSA. This thesis attempted to evaluate if there was a change in compliance
when a MAD was added as a combination therapy to moderate to severe OSA subjects that were
currently non-compliant with their CPAP. In addition, the change in air pressure, Epworth
Sleepiness Scale (ESS) scores, Apnea-Hypopnea Index (AHI) scores, and mask leaks were
examined. Combination therapy showed a statistical significant increase in compliance (+23.1%)
and decrease in ESS scores (-1.4) compared to CPAP therapy alone. There was also a decrease in
air pressure (-0.1846 cmH2O), AHI scores (-0.07), and mask leaks (-0.8538 leaks/min), but these
decreases were not significant.
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CHAPTER 1: INTRODUCTION
The treatment of obstructive sleep apnea (OSA) allows for a true multidisciplinary
approach between dentistry and medicine. OSA results from a collapse in the upper airway,
which blocks oxygen intake despite continued respiratory effort (Leinum et al., 2009). Patients
suffering from OSA experience increased morbidity such as heart failure, cerebrovascular insult,
impaired neuro-cognition, and poorly controlled mood disorder (Stansbury & Strollo, 2015).
Treatment of OSA was not a common practice in the dental profession until recently. The
use of the mandibular advancement device (MAD) for the treatment of OSA brought the
treatment into the dental field. A MAD is often considered as a first line of treatment in patients
with mild to moderate sleep apnea (Serra-Torres et al., 2016). However, a MAD is also used as
an alternative in patients exhibiting suboptimal compliance with continuous positive airway
pressure (CPAP) therapy due to CPAP intolerance (Kushida et al., 2006). The most common
complaints associated with CPAP wear were the discomfort of the apparatus and the intolerance
to air pressure (Gay et al., 2006). Improvements in CPAP and mask designs have changed
tremendously to attempt to improve compliance. Although there were unwanted effects to the
dentition associated with the MAD, patients subjectively prefer to use the MAD for treatment of
sleep apnea instead of the CPAP (Hoffstein, 2007).
The MAD works by increasing the retropalatal and retrolingual spaces while decreasing
the length of the soft palate and the angle of mouth opening (Lee et al., 2009). The drawback of
the MAD is its decreased effectiveness in improving AHI scores when compared to the CPAP
(Gagnadoux et al., 2009). One study showed that MADs reduced the average initial apneahypopnea index (AHI) by 42% while the more efficient CPAP reduced AHI scores by 75% (Gay
et al., 2006). An additional study showed similar results of 42.8% AHI reduction with the MAD
versus 73.2% with the CPAP (Ramar et al., 2015). Results showed that the best use of the MAD
is in patients with a mild-to-moderate sleep apnea (Gay et al., 2006).
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Clinicians are faced with the dilemma of choosing between the CPAP, which is highly
effective but has suboptimal compliance, and the MAD, which is less effective but has greater
compliance. The suboptimal compliance to CPAP undermines its effectiveness in treating OSA.
The most critical time of the treatment is right after the patient is given their appliance, whether
it’s a MAD or CPAP. Time is needed to adapt to the appliance due to the possible physical
interferences in sleep and jaw function. The extent to which a patient will use an appliance is
determined in the first month of treatment (Kribbs et al., 1993). While the CPAP and MAD have
been around for years, it was only recently that a combination of the two treatments was studied.
A pilot study, which looked at the efficacy of combination therapy, found that the combination
treatment reduced the optimal CPAP pressure by 36% and decreased the apnea hypopnea index
(AHI) score by 86% versus MAD alone. The subjects in this study also tolerated the combination
therapy very well (El-Solh et al., 2011). Our study is the first to evaluate the efficacy of
combination therapy with subjects diagnosed with moderate to severe sleep apnea. In addition,
all subjects in our study used an automated CPAP, which recorded the parameters including air
pressure, duration of use, AHI value, and mask leaks while in use.
With the continued problem of suboptimal CPAP compliance in OSA treatment,
combination CPAP-MAD therapy offers a promising alternative. This study aims to improve the
body of scientific knowledge regarding the efficacy and compliance of the CPAP-MAD
combination therapy. If the combination therapy is shown to be highly effective and well
tolerated in treating OSA, this novel multidisciplinary approach can vastly improve the quality of
life for numerous patients.
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CHAPTER 2: LITERATURE REVIEW
2.1 Sleep Disordered Breathing
Sleep disordered breathing (SDB) is a term that is used to describe several sleep-related
abnormalities, including obstructive sleep apnea (OSA), central sleep apnea, and hypoventilation.
SDB is defined by sporadic periods of apnea, hypopnea, or respiratory effort-related arousals
(RERAs) (Panossian & Daley, 2013). OSA syndromes include those where there is a blockage of
the airway causing increased breathing effort and inadequate ventilation. Central sleep apnea
(CSA) has an unknown cause but is defined by repeated episodes of cessation of breathing during
sleep without associated ventilatory effort (Cowie, 2017). CSA is often associated with heart
failure, but it has also been seen in patients with stroke, renal failure or opiate use (Cowie, 2017).
Hypoventilation syndromes include several disorders, but all are related to an elevation of arterial
carbon dioxide tension or reduced oxygen saturation during sleep (Thorpy, 2012). There is a
subtype of SDB called upper airway resistance syndrome (UARS) where the patient primarily
suffers from RERAs, without exhibiting significant oxygen desaturations or apneas and
hypopneas. The respiratory issues that happen in SDB are often temporary and self-limited
(Panossian & Daley, 2013). OSA is the most common disease within SDB (Cowie, 2017).
2.2 Obstructive Sleep Apnea
Obstructive sleep apnea results from the upper airway collapsing during sleep, which
blocks oxygen intake despite continued respiratory effort (Leinum et al., 2009). A systematic
review suggested that the most important anatomical characteristic of the upper airway related to
the pathogenesis of OSA is a small cross-sectional area (Chen et al., 2016). The airway blockage
is often associated with cortical microarousals and oxygen desaturation, which in turn leads to
sleep disruption and increased sympathetic neural activity (Caples et al., 2005). The cost burden
of OSA and its comorbidities is extremely high. In 2015, it was estimated that the cost burden for
the diagnosis and treatment of OSA in the United States was 12.4 billion dollars. Even more
staggering is the cost burden of undiagnosed OSA in the United States; in 2015 it was 149.6
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billion dollars. This number factored in comorbidities and mental health, motor vehicle accidents,
workplace accidents and lost productivity (Frost and Sullivan, 2016).
2.3 Prevalence of OSA
The prevalence of obstructive sleep apnea has seen a substantial increase in the last 20
years. One study found the prevalence of moderate to severe OSA is 10% for men 30-49 years
old, 17% for men 50-70 years old, 3% for women 30-49 years old, and 9% for women 50-70
years old (Peppard et al., 2013). Over the 20 years prior to this study, these prevalence numbers
have increased anywhere from 14% to 55% depending on the age group (Peppard et al., 2013).
Across the world the prevalence of OSA ranges from 6% to 49% (Senaratna et al., 2017).
Increased prevalence of OSA may be due to higher rates of obesity and the increased testing for
OSA (Kunisaki et al., 2016). The ratio of men to women with clinically significant sleep apnea
(AHI ≥10 with daytime symptoms) was 3.3:1 (Bixler et al., 2001). Risk factors for OSA include
old age, male gender, African-American or Asian ethnicity, short neck, retrognathia, obesity, and
heart failure (Cowie, 2017). While OSA is often considered to be a disease affecting adults, the
prevalence of childhood OSA is on the rise as well. OSA affects 1% to 6% of all children and up
to 59% of obese children (Schwengel et al., 2014). OSA is the most common respiratory disorder
to be acknowledged as a serious public health problem (Ahrens et al., 2011).
2.4 Diagnosis of OSA
The gold standard for diagnosing OSA is the overnight polysomnogram (PSG) (Lee et
al., 2008). The PSG includes several physiologic recordings including electroencephalogram,
electrooculogram, electrocardiogram, chin and leg electromyograms, body position, finger pulse
oximetry, measurements of airflow, and measurements of thoracic and abdominal respiratory
effort (Lee et al., 2008). In the traditional model, primary care providers refer patients with
suspected sleep apnea to a sleep specialist physician. The patient’s first visit with the specialist
includes a consultation, followed by an appointment scheduled for an in-lab PSG that may or may
not include a Continuous Positive Airway Pressure (CPAP) titration. The problems with this
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traditional model are expense and ineffectiveness for evaluation and treatment of patients at high
risk of OSA (Phillips et al., 2015). Some newer models use at home sleep testing (HST) for the
diagnosis, followed by administration of an auto-titrating CPAP device, which automatically
adjusts the pressures to keep the airway patent during sleep (Collop et al., 2007, Morgenthaler et
al., 2008). The HST usually monitors oxygen saturation, nasal airflow and chest and abdominal
movement (figure 2.1) (Cowie, 2017). One study found that evidence showed the HST with autotitratable CPAP provided similar results to fixed pressure CPAPs titrated from an in lab PSG
(Kunisaki et al., 2016). The Portable Monitoring Task Force, appointed by the American
Academy of Sleep Medicine (AASM), says that the HST should only be used in conjunction with
a comprehensive sleep evaluation from a board certified sleep specialist (BCSS) (Collop et al.,
2007). Figure 2.2 depicts a flow chart to represent a pathway for patients to be considered for
portable device monitoring (PM). The taskforce says HST should not be used for diagnosis in
patients with significant comorbid medical conditions, patients with other sleep disorders, or as
general screening of the asymptomatic population (Collop et al., 2007). Both PSG and HST use
the same type of scoring for the OSA diagnosis. The presence and severity of the sleep apnea is
determined through a score on the apnea-hypopnea index (AHI). The AHI defines the average
number of apneas and/or hypopneas a patient has per hour (Lee et al., 2008). An apnea is defined
as a reduction in airflow greater than or equal to 90% of baseline for at least 10 seconds, while
hypopnea is defined as a reduction in airflow greater than or equal to 30% of baseline for at least
10 seconds that is associated with a 4% reduction in oxygen saturation (Stansbury & Strollo,
2015). In adults, if the patient has an AHI less than 5, it is considered normal. If a patient has an
AHI above 5 but below 15, it is considered as having mild sleep apnea. Moderate sleep apnea is
defined as an AHI above 15 but below 30, while severe sleep apnea is any AHI score over 30
(Lee et al., 2008). Several subjective tests can also be administered to measure daytime
sleepiness. Many of these subjective tests include questionnaires to establish whether the patient
suffers from daytime sleepiness (Lee et al., 2008). One study looked at three OSA screening
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questionnaires (SACS, Berlin and STOP-Bang) and the results showed that none of the three had
adequate sensitivity and specificity to be sufficiently reliable in a clinical setting to rule in or to
rule out OSA (Pereira et al., 2013). The accuracy and reliability of the questionnaires varies
depending on the diagnostic AHI used. When an AHI threshold of 5 events/hour was used, the
questionnaires showed a higher sensitivity and specificity (Chung et al., 2008, Sharma et al.,
2006). Out of four screening questionnaires (Berlin, STOP-BANG, STOP, and Epworth
Sleepiness Scale (ESS)) the STOP-BANG was shown to be the most accurate tool for detecting
mild, moderate, and severe OSA (Chiu et al., 2016).
2.5 Health and OSA
Deleterious effects of OSA are due to airway obstruction, associated activation of the
sympathetic nervous system, hemodynamic issues, and sleep disruption (Leinum et al., 2009).
People suffering from untreated OSA have exhibited increased inflammation with elevated levels
of inflammatory mediators such as tumor necrosis factor-alpha, interleukin 1β, interleukin 6,
ICAM, coagulation factors (factor VIII), and C-reactive protein (Kokturk et al., 2005, Minoguchi
et al., 2004, Ohga et al., 2003, Ryan et al., 2005, Yokoe et al., 2003). Untreated OSA has been
associated with cardiovascular disease, cancer, chronic obstructive pulmonary disease (COPD),
stroke, and type II diabetes (Leinum et al., 2009). OSA as a risk factor for arterial hypertension
has been well documented. There is a strong bi-directional relationship between OSA and arterial
hypertension, with about 30-40% of patients with arterial hypertension exhibiting clinically
relevant OSA and about 50% of patients with OSA having arterial hypertension (Somers et al.,
2008). Prevalence of arterial hypertension increases with the severity of OSA (Hla et al., 1994).
OSA is associated with an increased risk for congestive heart failure in middle-aged and older
men (Gottlieb et al., 2010).
Over half of patients with paroxysmal or persistent atrial fibrillation (AF) have
exemplified SDB (Bitter et al., 2010). Severe OSA has been shown to increase the risk of AF,
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ventricular premature beats, non-sustained ventricular tachycardia, and nocturnal sudden cardiac
death (Mehra et al., 2006).
Prevalence of coronary artery disease (CAD) is much higher in patients with OSA than
the general population (Andreas et al., 1996). Men have a 68% higher chance of developing CAD
when they suffer from severe sleep apnea (Gottlieb et al., 2010). Patients who have suffered a
stroke often have OSA, and the prevalence of this occurrence is 71% based on case-controlled
studies (Arzt et al., 2005). Not only is there a correlation between OSA and the risk of stroke, but
OSA is also an independent risk factor for a subsequent stroke (Dziewas et al., 2005).
With obesity being one of the main risk factors for OSA, it’s not surprising that there is a
high prevalence of OSA patients with type 2 diabetes mellitus. The Sleep Heart Health Study
showed that OSA was associated with impaired fasting glucose, glucose intolerance, and type 2
diabetes mellitus (Punjabi et al., 2004).
While OSA doesn’t cause COPD, it can make the problems of COPD much worse. OSA
may exacerbate COPD through vagally-mediated bronchoconstriction and an increase in resistive
load in the lower airways due to high negative intrathoracic pressure (Ioachimescu & Teodorescu,
2013). Patients with COPD and OSA suffer from high rates of morbidity and mortality as well as
a decreased quality of life (Shaya et al., 2009).
The association between OSA and cancer is hypothesized to be a direct result of
repetitive hypoxia (Leinum et al., 2009). When cancer cells are subjected to repetitive hypoxia in
vitro, instantaneous angiogenesis occurs which in turn causes a proliferation of blood vessels and
cancer cells (Harris, 2002). In animal experiments, intermittent hypoxia has been linked with
increased tumor cell proliferation and metastases (Almendros et al., 2014).
2.6 Treatment Availabilities of OSA
Treatment of OSA requires a multidisciplinary approach that includes the medical and
dental fields. The American Academy of Sleep Medicine (AASM) and the American Academy of
Dental Sleep Medicine (AADSM) have collaborated to develop treatment guidelines. Their meta-
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analysis showed that there was no significant difference between oral appliances and Continuous
Positive Airway Pressure (CPAP) in the percentage of mild OSA patients achieving their target
AHI (Ramar et al., 2015). When it came to patients with moderate to severe OSA, the chances of
reaching the target AHI were significantly greater with the CPAP than the oral appliance (Ramar
et al., 2015). The academies recommend that sleep physicians consider prescribing an oral
appliance for adult OSA patients that aren’t tolerant of CPAP therapy or prefer an alternative
approach (Ramar et al., 2015).
2.6.1 Continuous Positive Airway Pressure Treatment of OSA
The use of Continuous Positive Airway Pressure (CPAP) is considered the gold standard
for OSA treatment (Spicuzza et al., 2015); however, CPAP compliance is one of the biggest
challenges. CPAP users have shown average non-adherence rates of 36% (Rotenberg et al.,
2016). Patient education, health and quality-of-life benefits, proper mask selection, and
supportive management of adverse effects are all ways to increase adherence (Cowie, 2017).
Common side effects of CPAP usage are mask leakage, mask pressure, dry mouth, nasal
stuffiness, claustrophobia, and difficulties exhaling (Brostrom et al., 2010). Nasal obstruction, dry
mouth and an increased number of awakenings were side effects that were found to lower
objective adherence (Ulander et al., 2014). Patients that experienced side effects or anxiety in the
first 2 weeks of CPAP treatment were more likely to stop using the CPAP in the first year
(Ulander et al., 2014). Also, patients that reported CPAP problems on the first night were less
likely to maintain compliance (Lewis et al., 2004).
Initially, CPAP therapy was delivered at a fixed pressure that was determined during an
overnight titration study (Vennelle et al., 2010). More recently, the CPAP therapy is often
prescribed using a device that can vary the pressure delivered. The advantages of these variable
pressure CPAPs are the ability to adjust the pressure based on factors such as posture, alcohol,
nasal congestion, weight change, and older age (Vennelle et al., 2010). In one randomized
controlled study comparing fixed versus variable pressure, results showed slightly improved ESS
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scores and CPAP use with variable pressure CPAP. (Vennelle et al., 2010). The ESS score
difference was 0.6 and the difference in average CPAP use was 0.2 h/night (Vennelle et al.,
2010). There were no significant differences in objective sleepiness, vigilance, quality of life or
nocturnal symptoms (Vennelle et al., 2010). Patients also had no preference between the two
methods (Vennelle et al., 2010).
Another point of variance between CPAPs is the mask selection. The four types of masks
used are the nasal mask, the oro-nasal mask, the nasal pillows and the oral masks (figure 2.3).
The nasal pillows have a higher initial acceptance, and they have been proven to be effective even
at higher pressures (>12 cmH2O) (Zhu et al., 2013). Oro-nasal masks often require higher CPAP
air pressure levels and are associated with a higher residual AHI and lower compliance rate
(Bettinzoli et al., 2014). Oral masks have been shown to be effective because they hold the
tongue in place with a tongue guide, however, their acceptance is very low (Andrade et al., 2014).
Nasal masks and nasal pillows are recommended as the first choice, but if oro-nasal masks are
prescribed they need to be monitored closely due to the risk of failure (Andrade et al., 2014).
2.6.2 Oral Appliances for Treatment of OSA
Oral appliances for treating OSA include mandibular advancement devices, tongue
retaining devices, and soft palate lifters (Schmidt-Nowara et al., 1995). MADs (mandibular
advancement devices) are the most commonly used oral appliance in OSA therapy (SchmidtNowara et al., 1995). The American Academy of Sleep Medicine suggested the use of oral
appliances in patients suffering from snoring, mild-to-moderate OSA, or severe OSA if CPAP has
failed (Kushida et al., 2006). MADs are used on average 1.1 hours a night more than CPAPs
(Schwartz et al., 2017).
A CBCT study showed that a mandibular advancement device increased the
anteroposterior dimension at the smallest cross-section of the airway by an average of 3.02 mm
and in the transverse dimension by an average of 4.27 mm (figure 2.4) (Shete & Bhad, 2017).
Another study showed that airway collapse occurs in the anteroposterior direction when a patient
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is in centric occlusion, but when the mandible is advanced the airway collapse is observed in the
transverse dimension (Isono et al., 1997).
Several types of mandibular advancement appliances have been created for OSA
treatment. Some appliances have a fixed advancement, where the distance of advancement can’t
be adjusted, whereas others are adjustable. The Herbst appliance, an adjustable MAD, has been
shown to provide better results for daytime sleepiness (Itzhaki et al., 2007). One study showed
that adjustable appliances resulted in a greater reduction in AHI and improvements in ESS
compared to fixed appliances (Lettieri et al., 2011). Prefabricated appliances have been shown to
be less effective than custom-made appliances (Vanderveken et al., 2008).
MADs have a variety of side effects with many of them being only temporary. Side
effects were reported in a little over 50% of patients and include jaw discomfort, tooth tenderness,
excessive salivation and occlusion changes (Mehta et al., 2001). The compliance rates for MAD
are higher than those for CPAPs, and MADs are often preferred by patients when given the
choice (Gagnadoux et al., 2009, Tan et al., 2002). A pilot study investigating the use of
combination therapy of CPAP with a MAD showed that the pressure needed to reduce obstructive
events was reduced. Daytime sleepiness was also reduced with the combination therapy (El-Solh
et al., 2011).
Another form of oral appliance is a tongue retaining device (TRD). TRDs work by
suctioning the tongue into an anterior bulb, which moves the tongue forward and widens the
upper airway dimensions (Randerath et al., 2011). A randomized study showed similar AHI
reduction in mild to moderate OSA patients using TRDs and MADs; however, patients preferred
to use the MAD (Deane et al., 2009).
2.6.3 Other Non-Surgical Treatments for OSA
The least invasive treatment modality for OSA is lifestyle change. Weight loss is one of
the most effective methods of reducing AHI scores. A 10% weight loss has been predicted to
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have a 26% decrease in AHI score (Peppard et al., 2000). A meta-analysis showed that weight
loss programs resulted in a mean reduction in AHI of 6 events/hour (Araghi et al., 2013).
Positional therapy can also be effective for patients that sleep on their backs. The use of a
wedge or sewing items on the back of shirts to make it uncomfortable to sleep on your back are
two ways to help break the supine sleeping habit (Cowie, 2017). Alcohol, sedatives, narcotics and
muscle relaxants should be avoided due to the increased chance of upper airway muscle tone
reduction (Cowie, 2017).
Myofunctional therapy has been prescribed as a treatment for OSA in some patients. The
therapy involves exercising the soft palate, tongue, and facial muscles and addressing
stomatognathic functions. Soft palate exercises were pronouncing a vowel intermittently (isotonic
exercise) and continuously (isometric exercise) daily for three minutes. The tongue exercises
included brushing the super and lateral surfaces of the tongue while the tongue is positioned on
the floor of the mouth (five times of each movement, three times a day), placing the tip of the
tongue against the front of the palate and sliding it backwards (three minutes a day), forced
tongue sucking upward against the palate (three minutes a day), and forcing the back of the
tongue against the floor of the mouth while keeping the tip of the tongue in contact with the lower
incisors (three minutes a day). The facial muscle exercises included orbicularis oris muscle
pressure, suction movements contracting only the buccinators, recruitment of the buccinator
muscles against a finger in the oral cavity pressing the muscle outward, alternated elevation of the
mouth angle muscle, and lateral jaw movements. The stomatognathic function exercises included
forced nasal inspiration and oral expiration in conjunction with saying open vowels, balloon
inflation with prolonged nasal inspiration and forced mouth expiration, and bilateral chewing of
bread using the tongue in the palate with closed teeth and no perioral contraction (Guimaraes et
al., 2009). A meta-analysis showed that myofunctional therapy reduced the AHI score in adult
patients by 50% and in children by 62% (Camacho et al., 2015).
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In some OSA cases, drug therapies have been used. These drugs aim to treat the OSA by
increasing respiratory drive, changing sleep structure, increasing upper airway muscle tone,
changing respiratory and cardiovascular reflexes, and/or reducing surface forces that encourage
closure of the upper airway (Randerath et al., 2011). Acetazolamide was administered to inhibit
carbonic anhydrase, which produced metabolic acidosis that increased respiratory drive (Whyte et
al., 1988). Drugs that facilitate an increase in serotonin have been evaluated for their possible
improvement of REM sleep, but they have all been shown to be ineffective for the treatment of
OSA (Brownell et al., 1982, Kraiczi et al., 1999, Marshall et al., 2008). One study showed a
significant reduction in AHI using cholinergic agonists, but it is still not recommended due to the
lack of long-term follow-up (Hedner et al., 2003). Drug therapies that focus on decreasing nasal
obstruction using nasal steroids have been scarcely studied in adults, but have shown success in
treating children with upper airway obstruction due to adenotonsillar hypertrophy. One study in
adults showed a modest decrease in AHI score, however, no improvements in oxygenation
indices, sleep quality or snoring noise were observed (Kiely et al., 2004).
2.6.4 Surgical Treatment of OSA
Nasal obstruction has been demonstrated to cause an increased number of arousals, more
frequent sleep stage changes, and/or an increase in the number of apneas and hypopneas (Lavie et
al., 1983). A review of evidence showed that nasal surgery as a single intervention is not
recommended for treating OSA, but it is recommended for reducing high therapeutic CPAP
pressures that are caused by nasal obstruction (Randerath et al., 2011).
Tonsillectomy and tonsillotomy are additional surgical approaches being recommended
for the treatment of OSA. The reasoning behind this is the upper airway anatomical structures
correlating with OSA include an enlarged tongue, thick soft palate, long and thick uvula, and/or
hypertrophic tonsils (Randerath et al., 2011). Evidence shows that the only time tonsillectomy is
recommended as a single intervention is in the presence of tonsillar hypertrophy.
Adenotonsillectomy is recommended as treatment for children with OSA if there is adenotonsillar
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hypertrophy (Randerath et al., 2011). In order to decrease the morbidity associated with surgical
tonsillectomy, radiofrequency tonsil reduction has been introduced (Friedman et al., 2003).
In the past, one of the most common surgical treatments for OSA was
uvulopalatopharyngoplasty (UPPP). UPPP works by increasing the retropalatal airway through
trimming and reorienting the posterior and anterior lateral pharyngeal pillars, as well as excising
the uvula and posterior soft palate (Won et al., 2008). The issue is that in OSA the upper airway
can collapse at multiple levels and UPPP is only successful when the problem is limited to the
retropalatal area. This is rarely the case in severe sleep apneic patients (Sher, 2002). Although
UPPP may appear beneficial in the short-term, the efficacy diminishes over time, and overall the
procedure is less effective than the use of an oral appliance (Walker-Engstrom et al., 2002). A
newer approach to the UPPP is a uvulopalatal flap. Tonsillectomies are performed with each
procedure. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula is first
removed. The uvular tip is then amputated and the uvula is reflected back toward the soft palate
and fixed with sutures (Powell et al., 1996). The uvulopalatal flap achieves the same results as the
UPPP, but there is less postoperative discomfort, less risk of developing velopalatal insufficiency,
and fewer complaints of a thickened foreign body sensation (Neruntarat, 2011). The uvulopalatal
flap shows significant decreases between short-term and long-term results, but has an
approximately 50% long-term success rate (Neruntarat, 2011). Uvulopalatal flaps can be
recommended for treating OSA patients that have a palatal obstruction (Randerath et al., 2011).
One surgical approach that is as effective as CPAP therapy in patients with OSA is the
maxillomandibular advancement (MMA) (Randerath et al., 2011). This surgery requires an
advancement of the maxilla and mandible 10-15mm when there is no maxillomandibular
abnormality. The surgery enlarges the retrolingual and retropalatal airway (Hochban et al., 1994).
The main disadvantage of the MMA is the plethora of side effects that can accompany the
surgery. These complications include cardiac arrest without sequellae and dysrhythmia, local
infection, perforation of the palate, maxillary pseudoarthrosis, malocclusion, and dysgnathia (Li
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et al., 2000, Riley et al., 1989, Waite et al., 1989). In addition, patients develop transient
anesthesia of the cheek and chin. Residual neurosensitive deficit was the most common
complication, but this didn’t affect the patient’s view on their quality of life (Randerath et al.,
2011).
Another surgical approach to treat OSA is hypoglossal nerve stimulation. An implantable
device is placed to stimulate the hypoglossal nerve in response to apnea or hypopnea. The
mechanism of action is a unilateral stimulation of the hypoglossal nerve to activate the
genioglossus muscle. The activated genioglossus muscle causes an anterior displacement of the
tongue and dilation of the pharynx, which leads to a relief of the airway obstruction (Schwartz et
al., 2001). One study showed a mean AHI reduction of 68% over 12 months using this therapy
(Strollo et al., 2014). Another study observed that hypoglossal nerve stimulation demonstrated the
adverse effect of patient arousal due to muscle contraction (Oliven et al., 2007).
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Fig 2.1 Polygraph reading from a patient with OSA. The top panel is noise related to
snoring, second panel is nasal air flow, third panel is thoracic and abdominal wall movement,
fourth panel is arterial oxygen saturation, and the fifth panel is pulse rate. (Cowie, 2017)
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Fig 2.2 Flow chart representing a pathway for patients to be recommended for portable
monitoring (PM) or polysomnography (PSG). Good candidates for PM should have
moderate to high risk for OSA, no comorbid medical conditions and no comorbid sleep
disorders. (BCSS = Board Certified Sleep Specialist) (Collop, et al., 2007)
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Fig 2.3 Photographs of the different types of CPAP masks. A: nasal mask, B: oronasal
mask, C: nasal pillows, D: oral mask (Andrade et al., 2014)
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Fig 2.4 Lateral, anterior, and posterior views of the upper airway before (a) and during
(b) mandibular advancement device therapy (Shete & Bhad, 2017).
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CHAPTER 3: STUDY AIMS
3.1. Statement of the Problem
Treatment of obstructive sleep apnea with CPAP can be highly ineffective due to low
compliance rates with CPAP wear. MADs have become an alternative treatment for sleep apnea,
however, with much lower success rate in reducing AHI in moderate to severe obstructive sleep
apnea. While the MAD was less effective in reducing the AHI in moderate to severe sleep apnea,
the compliance rates for wearing the MAD were much higher than the CPAP. CPAP and MAD
therapy are frequently used in treatment of OSA, however the scientific knowledge regarding the
efficacy and compliance of CPAP-MAD combination therapy is lacking.
3.2. Null Hypothesis
There is no difference in compliance of wear, air pressure, ESS, AHI, or mask air leaks
when comparing CPAP therapy alone to combination CPAP-MAD therapy in subjects with
moderate to severe obstructive sleep apnea.
3.3 Specific aims of the current study


Compare CPAP compliance rate before and during combination CPAP-MAD therapy



Compare air pressure values from CPAP alone to combination CPAP-MAD therapy



Compare Epworth Sleepiness Scores from CPAP alone to combination CPAP-MAD
therapy



Compare AHI scores from CPAP alone to combination CPAP-MAD therapy



Compare CPAP mask air leaks from CPAP alone to combination CPAP-MAD therapy
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CHAPTER 4: MATERIALS & METHODS
4.1 Subject acquisition
All subjects were patients of the University of Nebraska Medical Center (UNMC) Sleep
Medicine Clinic. Each subject had previously been diagnosed with moderate or severe sleep
apnea via a polysomnography (PSG) and had been prescribed continuous positive airway pressure
(CPAP) for at least 6 months. Suboptimal compliance with the CPAP had been documented
within 3 months prior to recruitment and was defined as using the device less than or equal to 4
hours a night for greater than or equal to 30% of the nights. Each subject had a complete or
functional dentition to support a mandibular advancement device (MAD). The inclusion and
exclusion criteria are listed in figure 4.1. The study was started as a randomized clinical control
study, where the subjects would be randomly chosen to receive either a MAD or a sham occlusal
splint. In recruitment, we only had one subject willing to volunteer, and therefore the study was
changed to a crossover study. A letter was sent out to prospective subjects as a tool to increase
recruitment (figure 4.2)
4.2 CPAP protocol
All subjects were using a ResMed AirSense 10 AutoSet CPAP machine with the ability
to automatically upload a compliance report to ResMed AirView (cloud-based system) or an SD
card that can be uploaded for review. The compliance report consists of information regarding the
usage, pressure, apneas (number and central vs obstructive), and RERAs. The CPAP machine,
based on how much air pressure is needed to treat the airway obstruction, adjusts the pressure
automatically. The data used from the CPAP machine were the subject’s usage, 95th percentile air
pressure, AHI score and mask air leaks (figure 4.3). Subjects were instructed to wear their CPAP
throughout the experiment.
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4.3 MAD protocol
All subjects reported to the UNMC Adult Dental Clinic to see Dr. Jacob Stadiem.
Impressions of the upper and lower teeth were taken using Identic® 100 - hour stability alginate
and models were poured up immediately in buff stone. A George Gauge (figure 4.4-4.5) was
used to determine where the bite registration was recorded. A 5mm anterior bite fork was used for
vertical opening (figure 4.6). The initial bite registration was taken with the patient at 50% of
their anteroposterior range of motion. The bite registration was taken using Exabite® II NDS
vinyl polysiloxane. The stone models and bite registration were sent off to DynaFlex® labs for the
fabrication of an adjustable Herbst-design MAD (figure 4.7). The MAD was made with a thermal
acrylic material called Accu-Fit on the inside to allow for realignment at any time (figure 4.8). At
the second visit, the MAD was delivered and subjects were taught how to properly insert and
remove the MAD. Upon delivery of the MAD, subjects were asked to wear the appliance for 2
weeks with their CPAP and return to the UNMC Adult Dental Clinic for evaluation regarding the
wear. Each subject was instructed to wear a 3/16 inch 3.5 oz. elastic from upper to lower anterior
hook bilaterally every night (figure 4.9). After two weeks, subjects were assessed for comfort
with the appliance. If there was any temporomandibular joint discomfort, the appliance was
modified to decrease the vertical dimension. Subjects were then asked to wear the appliance for
another 2 weeks and return for an assessment. Four subjects needed vertical modification, but all
of them were symptom free at the following visit. When subjects were free of discomfort, they
were advanced to 70% of their anteroposterior range of motion (figure 4.10). Subjects were then
instructed to wear the MAD with their CPAP for four weeks. All data was recorded from the
ResMed CPAP machine.
4.4 Subjective assessment
Each subject was given an Epworth Sleepiness Scale survey at their first appointment at
the UNMC Adult Dental Clinic to assess their subjective daytime sleepiness (figure 4.11). After
the final 4-week session of combination therapy, each subject was again given an Epworth
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Sleepiness Scale survey. An increase in ESS score indicated an increase in daytime sleepiness
while a decrease in ESS score indicated a decrease in daytime sleepiness.
4.5 Statistical analysis
Means for 95th percentile pressure, compliance percentage, AHI value, and leaks were
determined for pre-treatment (CPAP only) and during treatment (combination therapy). Means
for ESS score pre-treatment and post-treatment were also determined. A paired two-sample T-test
was performed using SAS® to determine the significance of change in compliance, air pressure,
AHI, mask air leaks, and ESS score. An unpaired two-sample T-test of equal variance was
performed to determine the significance of the change in air pressure, compliance, and ESS score
between males and females. An unpaired two-sample T-test of unequal variance was performed
to determine the significance of the change in AHI and mask air leaks between males and
females. An F-test was run for each data comparison between males and females to determine
variance.
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Inclusion Criteria:
1. Confirmed diagnosis by polysomnogram of moderate to severe OSA as defined by an
AHI score of ≥15 within the preceding 2 years
2. Inability to tolerate CPAP or reported history of CPAP noncompliance as defined by
≤n4 hrs/night for ≥ 30% of the nights over the preceding 3 months
3. Complete or functional dentition
4. Ages of 21 and older
5. Auto-CPAP therapy using ResMed device that is linked to ResMed AirView or has
an SD card
Exclusion Criteria:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Patients on oxygen therapy
History of alcohol, narcotic, or daily sedating psychoactive medications
Serious nasal passage obstructions or allergies that would prevent the CPAP use
Previous history of surgical treatments including uvulopalatopharyngoplasty or BSSO
mandibular advancement
Age < 21
History of Temporomandibular joint dysfunction (TMD)
Significant weight loss or gain (10%) since diagnosis
History of claustrophobia or nasal airway obstruction (such as uncontrolled allergic
rhinitis)
Other untreated sleep disorders (e.g. PLMD, RLS, Narcolepsy, CSA or insomnia)
History of CHF, COPD, or psychiatric disorder other than controlled anxiety and/or
depression

Fig 4.1 Inclusion and exclusion criteria for subject recruitment. All of the criteria were
confirmed before the subjects were seen for the first study visit other than the functional
dentition.
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Fig 4.2 Recruitment letter sent out to all prospective subjects.
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Fig 4.3 ResMed Airview summary. The report received directly from the CPAP machine.
95th percentile air pressure, usage percentage, AHI, and mask air leaks were recorded from
this summary.
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Fig 4.4 George gauge. Used to record the subject’s bite registration for MAD fabrication. The
numbers on the gauge indicate how far the subject can protrude and retrude their mandible.
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Fig 4.5 George gauge being used to record a subject’s mandibular anteroposterior range
of motion.
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Fig 4.6 George gauge bite forks. The white bite fork (right), which was used in our study,
has a 5mm vertical opening in the anterior. The grey bite fork (left) has a 2mm opening in the
anterior.
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Fig 4.7 Herbst style mandibular advancement device. The red dot on the maxillary arch in
the anterior indicates to the subject which arch is the top. The red dot on the sides signifies the
direction to turn the bolt to increase the protrusion. Sixteen turns is equal to 1mm of
advancement.
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Fig 4.8 Accu-Fit material in the Herbst style MAD. Accu-fit is a thermal acrylic material
that allows you to remold the appliance by heating in a hot water bath. Every appliance was
able to be fit on the delivery day.
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Figure 4.9 Elastics worn on the Herbst style MAD. The use of the elastics was used to
make sure the subject’s mouth did not open during sleep.
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Fig 4.10 MAD appliance advanced to 70% of full anteroposterior range. Subjects wore
elastics from upper hook mesial to the canine to the lower hook on the same side.
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Fig 4.11 Epworth Sleepiness Scale Survey. Used to record subjective daytime sleepiness.
Each subject was given the survey before the combination therapy and at the end of
combination therapy. (Johns, 1992)
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CHAPTER 5: RESULTS
5.1 Patient Acquisition
Forty-eight subjects from the UNMC Sleep Medicine clinic met the initial inclusion and
exclusion criteria. After contacting potential subjects, eighteen subjects showed interest in
participating in this study. After initial recruitment, two subjects did not have a functional
dentition and three subjects decided not to go forward with the project. Thirteen subjects started
the study and all thirteen completed the study.
5.2 Demographics
The average age of the subjects at the start of the treatment was 61.6 years old with a
range from 45.9 to 73.7 years old. The gender makeup of the study was eight females (62%) and
five males (38%). The average AHI score, before any treatment, of the subjects was 40.6.
5.3 Changes in all recorded parameters before and during treatment
There were significant changes and non-significant changes in parameters recorded in
this study. This is shown in Table 5.1.
5.4 Compliance percentages
The average pre- and post-treatment for percentage compliance of CPAP wear for all
subjects is shown in figure 5.1. Error bars represent the upper and lower 95% confidence limits of
each measurement. A box-plot representing the data is shown in figure 5.2. A summary of the
paired two-sample T-test is shown in appendix B. P-value for all compliance percentages was set
at <0.05. Nine out of the thirteen subjects (69%) showed an increase in compliance percentage,
three out of thirteen subjects (23%) exhibited a decrease in compliance percentage, and one out of
thirteen subjects (8%) exhibited no change in compliance percentage. An average increase in
compliance percentage of 23.0769% with combination therapy was statistically significant
(p=0.0154). Males had a 9% larger increase in compliance percentage, but the difference was not
significant (p = 0.6024) (appendix B).
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5.5 CPAP Air Pressure Levels
The average pre- and post-treatment measurements for CPAP air pressure on all subjects
are shown in figure 5.3. Error bars represent the upper and lower 95% confidence limits of each
measurement. A box-plot representing the data is shown in figure 5.4. A summary of the paired
two-sample T-test is shown in appendix B. P-value for all pressure measurements was set at
<0.05. Six out of the thirteen subjects (46%) showed a decrease in pressure, while seven out of
thirteen (54%) exhibited an increase in pressure used with the CPAP. An average decrease in
pressure of 0.1846 cmH2O was not statistically significant (p=0.6968). Males had a 1.23 cmH2O
larger decrease in air pressure but the difference was not significant (p = 0.2098) (appendix B).
5.6 Epworth Sleepiness Scale
The average pre- and post-treatment ESS scores for all subjects are shown in figure 5.5.
Error bars represent the upper and lower 95% confidence limits of each measurement. A box-plot
representing the data is shown in figure 5.6. A summary of the paired two-sample T-test is shown
in appendix B. P-value for all ESS scores was set at <0.05. Nine out of the thirteen subjects
(69%) showed a decrease in their ESS score, three out of thirteen subjects (23%) exhibited an
increase in their ESS score, and one out of thirteen subjects (8%) exhibited no change in their
ESS score. An average decrease in ESS score of 1.3846 with combination therapy was
statistically significant (p=0.0269). The average decrease in ESS scores for males was 1 point
lower than females, but this difference was not significant (p = 0.3992) (appendix B).
5.7 AHI values
The average pre- and post-treatment AHI values for all subjects are shown in figure 5.7.
Error bars represent the upper and lower 95% confidence limits of each measurement. A box-plot
representing the data is shown in figure 5.8. A summary of the paired two-sample T-test is shown
in appendix B. P-value for all AHI values was set at <0.05. Nine out of the thirteen subjects
(69%) showed a decrease in their AHI value indicating less obstructive events during sleep. Three
out of thirteen subjects (23%) exhibited an increase in their AHI value, indicating more
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obstructive events during sleep. One out of thirteen subjects (8%) exhibited no change in their
AHI value. An average decrease in AHI value of 0.0692 was not statistically significant
(p=0.9075). Females had a mean decrease in AHI value of 0.275 larger than the males, but this
difference was not significant (p = 0.8718) (appendix B).
5.8 Air Leaks with CPAP
The average pre- and post-treatment measurements for CPAP mask air leaks on all
subjects are shown in figure 5.9. Error bars represent the upper and lower 95% confidence limits
of each measurement. A box-plot representing the data is shown in figure 5.10. A summary of the
paired two-sample T-test is shown in appendix B. P-value for all leaks measurements was set at
<0.05. Six out of the thirteen subjects (46%) showed a decrease in leaks, while seven out of
thirteen (54%) exhibited an increase in leaks while using the combination therapy. An average
decrease in leaks of 0.8538 leaks/min was not statistically significant (p=0.7542). Females
exhibited a mean decrease of 0.54 mask air leaks greater than males, but this difference was not
significant (p = 0.9067) (appendix B).

37

Table 5.1 Mean changes for all subjects
Subjects =13
PreTreatment
Mean
12.4

PostTreatment
Mean
12.2154

Mean
Difference

SD

P-Value

Sig

-0.1846

1.6678

0.6968

NS

44.3077

67.3846

23.0769

29.4971

0.0154

*

7.6154

6.2308

-1.3846

1.9807

0.0269

*

AHI

2.0615

1.9923

-0.0692

2.1037

0.9075

NS

Leaks
(Leaks/min)

15.2154

14.3615

-0.8538

9.6105

0.7542

NS

Pressure
(cmH2O)
Compliance
Percentage
ESS
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Figure 5.1. Pre- and post-treatment mean compliance percentage. CPAP compliance rates
were measured three months prior to recruitment with the CPAP only and over a 4-week
period with combination therapy. Statistically significant increase in compliance percentage
observed (*p = 0.0154).
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Figure 5.2. A box-plot diagram comparing compliance percentage pre- and posttreatment. CPAP compliance rates were measured three months prior to recruitment with the
CPAP only and over a 4-week period with combination therapy. Black dot represents the
mean.
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Figure 5.3. Pre- and post-treatment mean 95th percentile air pressure. CPAP air
pressures were measured three months prior to recruitment with the CPAP only and over a 4week period with combination therapy.
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Figure 5.4. A box-plot diagram comparing 95th percentile air pressure pre- and posttreatment. CPAP air pressures were measured three months prior to recruitment with the
CPAP only and over a 4-week period with combination therapy. Black dot represents the
mean.
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Figure 5.5. Pre- and post-treatment mean ESS scores. ESS scores were measured at the
subject’s first visit with Dr. Stadiem and after a 4-week period with combination therapy.
Statistically significant decrease in ESS scores observed (*p = 0.0269).
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Figure 5.6. A box-plot diagram comparing ESS scores pre- and post-treatment. ESS
scores were measured at the subject’s first visit with Dr. Stadiem and after a 4-week period
with combination therapy. Black dot represents the mean.
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Figure 5.7. Pre- and post-treatment mean AHI values. AHI values were measured three
months prior to recruitment with the CPAP only and over a 4-week period with combination
therapy.
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Figure 5.8. A box-plot diagram comparing AHI values pre- and post-treatment. AHI
values were measured three months prior to recruitment with the CPAP only and over a 4week period with combination therapy. Black dot represents the mean.
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Figure 5.9. Pre- and post-treatment mean mask air leaks. Leaks were measured three
months prior to recruitment with the CPAP only and over a 4-week period with combination
therapy.

47

Figure 5.10. A box-plot diagram comparing leaks pre- and post-treatment. Leaks were
measured three months prior to recruitment with the CPAP only and over a 4-week period
with combination therapy. Black dot represents the mean.
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CHAPTER 6: DISCUSSION
6.1 Relevance of Study
The gold standard for obstructive sleep apnea is still CPAP therapy. The problem
associated with CPAP is the high non-compliance rate with CPAP wear. An effective treatment
modality that isn’t followed is no more beneficial than an ineffective treatment modality. The
main obstacles in achieving increased compliance with CPAP therapy were the side effects of the
CPAP. Non-adherence to the CPAP is most commonly due to increased awakenings and dry
mouth (Ulander et al., 2014). The goal of our study was to improve the compliance of CPAP wear
by delivering a MAD, to go along with the CPAP. The rationale of this thought process was
based on two facts. First, a MAD is preferred as an alternative to CPAP by patients (Hoffstein,
2007). Second, studies indicate that a MAD increased the volume of upper airway (Shete & Bhad,
2017). The increased airway volume may be of help in eliminating the discomfort from the
increased air pressure, which is needed to provide adequate airflow to treat the obstruction. A
MAD may help maintain air pressure at a lower level without compromising comfort for the
patient. This study was designed to record the duration of use of the CPAP after the MAD was
delivered. If the added MAD didn’t improve the subject’s comfort level, they were likely to stay
noncompliant.
6.2 Compliance percentages
The CPAP compliance percentage was measured through the ResMed AirView/SD card
and was calculated as the percentage of the 30 days the subject wore the CPAP ≥ 4 hours per
night. Our study showed a statistically significant difference in compliance percentage scores
(p=0.0154), indicating better compliance with the combination therapy. A person is considered
compliant with the CPAP if they wear the CPAP ≥4 hours a night for at least 70% of the nights
(Schwab et al., 2013). The average percentage of wear in our study with the CPAP-MAD
combination was 67.38%. Although the average percentage of wear was slightly under the 70%
mark, six out of the thirteen (46%) subjects eclipsed the 70% mark. Nine out of the thirteen
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subjects (69%) showed an increase in compliance percentage, with three subjects exhibiting a
97% compliance percentage. Although there was no significant decrease in air pressure, the
increase in compliance could be due to an increase in CPAP comfort with combination therapy.
The MADs ability to increase retropalatal and retrolingual spaces (Lee et al., 2009) may reduce
the air flow turbulence created during respiration. This decrease in turbulence could result in a
higher level of comfort. We only recorded compliance for the first month because it has been
shown that the compliance of the CPAP will be determined in the first month (Kribbs et al.,
1993). The increase in compliance may lead to a decrease in obstructive sleep apnea comorbidities. Combination therapy gives the sleep physician and dentist another treatment option
before resorting to a surgical therapy.
6.3 CPAP Air Pressure Levels
CPAP air pressure levels were measured through the ResMed CPAP machine. Each
machine automatically adjusted the pressure on a breath by breath basis to keep the airway open.
The auto-titrating CPAP was set by the sleep medicine doctors at a pressure range of 6-20
cmH2O. The average pressure used with the CPAP therapy alone was 12.40 cmH2O. With the
combination treatment, the average pressure recorded was 12.22 cmH2O, indicating a mean
difference of -0.18 cmH2O. Although the mean value decreased with the combination therapy, the
decrease was not statistically significant (p=0.6968). The reduction in air pressure could be nonsignificant due to a varied location of the upper airway minimal cross sectional area between
people. The oropharyngeal area has been reported as the most affected part of the pharynx in
OSA patients (Yucel et al., 2005), but the mandibular advancement device may not have affected
the exact location of the minimal cross sectional area. Our results vary from the pilot study
reported by El-Solh, et al. who found a significant difference of a 2.1 cmH2O decrease when
using the combination therapy (El-Solh et al., 2011). They compared the combination therapy
with an auto-titrating CPAP (APAP) to CPAP therapy alone with a fixed pressure CPAP. A metaanalysis showed that APAP pressures were on average 2.2 cmH2O less than fixed CPAP
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machines (Ayas et al., 2004). A reduction of 2.2 cmH2O would put their average change in air
pressure from CPAP alone to CPAP-MAD combination therapy at an increase of 0.1 cmH2O.
Therefore, we cannot compare our results directly to their results. Also, in their study, they
included subjects with mild, moderate and severe obstructive sleep apnea, and their subjects had a
much lower starting CPAP air pressure. Again, these parameters varied between our study and
their study, which would lead to differences in the results obtained. Furthermore, variations exist
between the mask types used by the subjects. In our patient pool, there were subjects using
oronasal, nasal, and nasal pillow masks. Their pilot study used only nasal masks on their subjects.
Oronasal masks have been shown to result in higher air pressures than nasal masks (Bettinzoli et
al., 2014). Mask types may influence the outcome of this study in terms of compliance, airleakage and pressure values. We did not have a large sample size to evaluate the outcome related
to mask type.
6.4 Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) survey was administered at the subjects’ MAD
fabrication visit and again at the end of the combination therapy. The average ESS score with
CPAP therapy alone was 7.62 and the average ESS score after combination therapy was 6.23, a
mean difference of -1.39. The difference in ESS scores showed statistical significance
(p=0.0269). The decrease in ESS score shows that subjectively the subjects felt less sleepy during
the day with the combination therapy compared with the CPAP therapy alone. The pilot study
from El-Solh, et al. showed an average decrease in ESS score from 12.7 to 7.5 when comparing
no therapy to the combination therapy, but they did not record an ESS score for the CPAP alone.
The ESS test-retest reliability has been shown to be reliable with no statistically significant
changes when there is no treatment between the first time the test is administered and the second
time. The ESS has also been shown to be reliable in reporting a reduction of daytime sleepiness
with OSA treatment (Johns, 1992). The ESS has also been proposed as a tool for identifying
OSA. For detecting mild OSA, the ESS was shown to have a sensitivity of 54% and a specificity
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of 65%. For moderate OSA, the ESS was shown to have a sensitivity of 47% and a specificity of
62%. For severe OSA, the ESS was shown to have a sensitivity of 58% and a specificity of 60%
(Chiu et al., 2016). The ESS is not the best tool for detecting sleep apnea, but it does seem
reliable when measuring a change in daytime sleepiness with OSA treatment. Our study
indicated, the patients were significantly compliant to the combination therapy compared to
CPAP alone.
6.5 AHI values
All of the subjects in our study had AHI scores in the therapeutic level (AHI < 5) with the
CPAP therapy alone. The average AHI before CPAP therapy, diagnosed from polysomnography,
was 40.6. The AHI scores ranged from 20.1 to 93.8. This again reinforces the fact that the gold
standard for the treatment of obstructive sleep apnea is CPAP therapy. The average AHI score
with the CPAP alone was 2.1 and with the combination therapy was 2.0, a mean difference of 0.1. Although there was a decrease in AHI score, this value was not significant (p=0.9075). There
was one outlier that had an increase in AHI of 6.1 with the combination therapy. With this outlier
removed the AHI score was reduced on average by 0.6, but still did not show statistical
significance (p = 0.07781). This outlier is likely due to an error in the machine reading. A larger
sample size could reveal whether a MAD in certain individuals may not be effective in changing
the airway. The AHI scores for our study were taken from the auto-titrating CPAP instead of
doing an HST or PSG. A study by Desai, et al. showed that the estimate of residual AHI by an
Auto-CPAP showed good agreement with the AHI determined from PSG (Desai et al., 2009).
Our subjects all showed a successful reduction in AHI (AHI < 5) with the CPAP alone. It was not
surprising that the combination therapy did not significantly reduce the AHI when these subjects
were already in the therapeutic range. While the reduction in AHI with combination therapy
wasn’t significant, when you combine a therapeutic AHI with an increased compliance
percentage, the combination therapy can be seen as a clinically successful.
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6.6 Air Leaks with CPAP
One potential problem with adding a MAD to an existing CPAP setup is the chance that
the mask won’t fit properly. Ideally, you would want the subject to be fit for a new mask with the
appliance to make sure the appliance isn’t causing the mask to leak. In our study we had the
subject continue wearing the mask they were currently using with the CPAP. The average mask
leaks with the CPAP therapy alone was 15.2 leaks/min and the average mask leaks with the
combination therapy was 14.4 leaks/min, a mean difference of -0.8 leaks/min. Although there was
a decrease in leaks, this difference was not significant (p=0.7542). Mouth opening, mean CPAP
pressure, sleep position and REM sleep have been shown to be factors that increase unintentional
leakage (Lebret et al., 2017). The use of elastics with the appliance to keep the subjects mouth
from opening in this study may have helped avoid unwanted leaks in our study. Mask air leaks
have been associated with poor adherence to CPAP and has been associated with side effects such
as oral dryness or nasal congestion (Borel et al., 2013, Valentin et al., 2011). Oronasal masks
have been shown to exhibit more mask leaks than nasal masks (Teo et al., 2011). This implies
that if patients use nasal masks along with CPAP- MAD therapy, a significant reduction in
leakage is possible, which could lead to a further improvement in air pressure and compliance.
6.7 Study Limitations and Future Studies
All subjects in this study were advanced to a 70% of the maximum anteroposterior range.
A titration of each appliance using HSTs could have possibly made these appliances more
effective because we would have the appliances at each subject’s most therapeutic position.
Our original power analysis based on the previously published pilot study showed that we
needed 12 subjects to show significance in the change of pressure and compliance (El-Solh et al.,
2011). From the results that we obtained, power analysis indicates we would actually need a
sample size of 641 to show significance level of 0.05 for a change in air pressure. This study
population is far from being able to reach this number. A larger sample size would also help in
seeing if there is a significant difference in the response to combination treatment by males and

53

females, any influence with mask designs, and whether MAD has deleterious effects on certain
individuals with OSA.
Again, we would like to emphasize the difficulty in recruiting patients for this type of
study, due to their lack of knowledge regarding an oral appliance and its effectiveness in
improving their sleep related problems. Not only patient’s unawareness leads to not utilizing the
available more effective therapy, the medical professional needs scientific evidence regarding this
approach of combination therapy and its effects on compliance of CPAP wear along with other
advantages discussed in this chapter, for a multidisciplinary approach in treating OSA patients.
Oral appliances are increasing in popularity with recent years, but randomized control clinical
trials are needed to further prove the effect to the scientific community and medical professionals.
Only after the medical professionals give their approval of this type of treatment can the lay
people truly grasp its contribution. Even with the small sample size, this study proves that there is
hope for the combination therapy and a multidisciplinary research approach is needed to exhibit
the results seen.
A randomized controlled trial with half of the subjects receiving a MAD and the other
half receiving a sham appliance would be an ideal study design for a meaningful result. The
chance of not receiving a MAD made many subjects very hesitant to participate.
A future addition to the study is to have each of these subjects go through an HST to see
how effective their MAD is as a single treatment. This will also give us the ability to compare the
effectiveness in reducing the AHI with the MAD alone to its ability to change the air pressure
during combination therapy.
Another future study option could be using CBCT to look at the effects of vertical versus
anteroposterior advancement of MADs on airway dimensions. There is a disagreement in the
literature on which direction the appliances should be adjusted to be more effective. Whether
more vertical opening of the jaw or more forward movement of the jaw would improve airway
dimensions needs to be answered. A CBCT measuring volumetric changes of the airway with
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vertical versus horizontal adjustment could help to better understand how to more effectively
construct the MAD.
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CHAPTER 7: CONCLUSION
In this study five variables regarding the CPAP- MAD combination therapy were
compared to CPAP therapy alone. The null hypothesis was rejected for two variables and
accepted for the other three. Compliance and ESS scores were changed significantly with the
combination therapy, whereas the air pressure, AHI scores, and mask air leakage did not show
any significant changes. Compliance percentages increased by an average of 23%, while ESS
scores decreased by an average of 1.4. A decrease in pressure, AHI, and leaks was observed as
well but this decrease was not statistically significant. Further studies, with improvements in
study design, are needed to fully assess the clinical efficacy of combination CPAP-MAD therapy.

56

BIBLIOGRAPHY
Ahrens A, McGrath C and Hagg U (2011). A systematic review of the efficacy of oral
appliance design in the management of obstructive sleep apnoea. Eur J Orthod 33: 318-24.
Almendros I, Wang Y, Becker L, Lennon FE, Zheng J, Coats BR, Schoenfelt KS,
Carreras A, Hakim F, Zhang SX, Farre R and Gozal D (2014). Intermittent hypoxia-induced
changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep
apnea. Am J Respir Crit Care Med 189: 593-601.
Andrade RG, Piccin VS, Nascimento JA, Viana FM, Genta PR and Lorenzi-Filho G
(2014). Impact of the type of mask on the effectiveness of and adherence to continuous positive
airway pressure treatment for obstructive sleep apnea. J Bras Pneumol 40: 658-68.
Andreas S, Schulz R, Werner GS and Kreuzer H (1996). Prevalence of obstructive sleep
apnoea in patients with coronary artery disease. Coron Artery Dis 7: 541-5.
Araghi MH, Chen YF, Jagielski A, Choudhury S, Banerjee D, Hussain S, Thomas GN
and Taheri S (2013). Effectiveness of lifestyle interventions on obstructive sleep apnea (OSA):
systematic review and meta-analysis. Sleep 36: 1553-62, 1562A-1562E.
Arzt M, Young T, Finn L, Skatrud JB and Bradley TD (2005). Association of sleepdisordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 172: 1447-51.
Ayas NT, Patel SR, Malhotra A, Schulzer M, Malhotra M, Jung D, Fleetham J and White
DP (2004). Auto-titrating versus standard continuous positive airway pressure for the treatment of
obstructive sleep apnea: results of a meta-analysis. Sleep 27: 249-53.
Bettinzoli M, Taranto-Montemurro L, Messineo L, Corda L, Redolfi S, Ferliga M and
Tantucci C (2014). Oronasal masks require higher levels of positive airway pressure than nasal
masks to treat obstructive sleep apnea. Sleep Breath 18: 845-9.
Bitter T, Westerheide N, Faber L, Hering D, Prinz C, Langer C, Horstkotte D and
Oldenburg O (2010). Adaptive servoventilation in diastolic heart failure and Cheyne-Stokes
respiration. Eur Respir J 36: 385-92.

57

Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A and Kales A
(2001). Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit
Care Med 163: 608-13.
Borel JC, Tamisier R, Dias-Domingos S, Sapene M, Martin F, Stach B, Grillet Y, Muir
JF, Levy P, Series F, Pepin JL and Scientific Council of The Sleep Registry of the French
Federation of P (2013). Type of mask may impact on continuous positive airway pressure
adherence in apneic patients. PLoS One 8: e64382.
Brostrom A, Arestedt KF, Nilsen P, Stromberg A, Ulander M and Svanborg E (2010).
The side-effects to CPAP treatment inventory: the development and initial validation of a new
tool for the measurement of side-effects to CPAP treatment. J Sleep Res 19: 603-11.
Brownell LG, West P, Sweatman P, Acres JC and Kryger MH (1982). Protriptyline in
obstructive sleep apnea: a double-blind trial. N Engl J Med 307: 1037-42.
Camacho M, Certal V, Abdullatif J, Zaghi S, Ruoff CM, Capasso R and Kushida CA
(2015). Myofunctional Therapy to Treat Obstructive Sleep Apnea: A Systematic Review and
Meta-analysis. Sleep 38: 669-75.
Caples SM, Gami AS and Somers VK (2005). Obstructive sleep apnea. Ann Intern Med
142: 187-97.
Chen H, Aarab G, de Ruiter MH, de Lange J, Lobbezoo F and van der Stelt PF (2016).
Three-dimensional imaging of the upper airway anatomy in obstructive sleep apnea: a systematic
review. Sleep Med 21: 19-27.
Chiu HY, Chen PY, Chuang LP, Chen NH, Tu YK, Hsieh YJ, Wang YC and
Guilleminault C (2016). Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP,
and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-analysis.
Sleep Med Rev.

58

Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A
and Shapiro CM (2008). STOP questionnaire: a tool to screen patients for obstructive sleep
apnea. Anesthesiology 108: 812-21.
Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel
D, Sateia M, Schwab R and Portable Monitoring Task Force of the American Academy of Sleep
M (2007). Clinical guidelines for the use of unattended portable monitors in the diagnosis of
obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American
Academy of Sleep Medicine. J Clin Sleep Med 3: 737-47.
Cowie MR (2017). Sleep apnea: State of the art. Trends Cardiovasc Med 27: 280-289.
Deane SA, Cistulli PA, Ng AT, Zeng B, Petocz P and Darendeliler MA (2009).
Comparison of mandibular advancement splint and tongue stabilizing device in obstructive sleep
apnea: a randomized controlled trial. Sleep 32: 648-53.
Desai H, Patel A, Patel P, Grant BJ and Mador MJ (2009). Accuracy of autotitrating
CPAP to estimate the residual Apnea-Hypopnea Index in patients with obstructive sleep apnea on
treatment with autotitrating CPAP. Sleep Breath 13: 383-90.
Dziewas R, Humpert M, Hopmann B, Kloska SP, Ludemann P, Ritter M, Dittrich R,
Ringelstein EB, Young P and Nabavi DG (2005). Increased prevalence of sleep apnea in patients
with recurring ischemic stroke compared with first stroke victims. J Neurol 252: 1394-8.
El-Solh AA, Moitheennazima B, Akinnusi ME, Churder PM and Lafornara AM (2011).
Combined oral appliance and positive airway pressure therapy for obstructive sleep apnea: a pilot
study. Sleep Breath 15: 203-8.
Friedman M, LoSavio P, Ibrahim H and Ramakrishnan V (2003). Radiofrequency tonsil
reduction: safety, morbidity, and efficacy. Laryngoscope 113: 882-7.
Gagnadoux F, Fleury B, Vielle B, Petelle B, Meslier N, N'Guyen XL, Trzepizur W and
Racineux JL (2009). Titrated mandibular advancement versus positive airway pressure for sleep
apnoea. Eur Respir J 34: 914-20.

59

Gay P, Weaver T, Loube D, Iber C, Positive Airway Pressure Task F, Standards of
Practice C and American Academy of Sleep M (2006). Evaluation of positive airway pressure
treatment for sleep related breathing disorders in adults. Sleep 29: 381-401.
Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline
S, Resnick HE, Tong EK, Diener-West M and Shahar E (2010). Prospective study of obstructive
sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study.
Circulation 122: 352-60.
Guimaraes KC, Drager LF, Genta PR, Marcondes BF and Lorenzi-Filho G (2009).
Effects of oropharyngeal exercises on patients with moderate obstructive sleep apnea syndrome.
Am J Respir Crit Care Med 179: 962-6.
Harris AL (2002). Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2:
38-47.
Hedner J, Kraiczi H, Peker Y and Murphy P (2003). Reduction of sleep-disordered
breathing after physostigmine. Am J Respir Crit Care Med 168: 1246-51.
Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB and Dempsey J (1994). Sleep apnea
and hypertension. A population-based study. Ann Intern Med 120: 382-8.
Hochban W, Brandenburg U and Peter JH (1994). Surgical treatment of obstructive sleep
apnea by maxillomandibular advancement. Sleep 17: 624-9.
Hoffstein V (2007). Review of oral appliances for treatment of sleep-disordered
breathing. Sleep Breath 11: 1-22.
Ioachimescu OC and Teodorescu M (2013). Integrating the overlap of obstructive lung
disease and obstructive sleep apnoea: OLDOSA syndrome. Respirology 18: 421-31.
Isono S, Tanaka A, Tagaito Y, Sho Y and Nishino T (1997). Pharyngeal patency in
response to advancement of the mandible in obese anesthetized persons. Anesthesiology 87:
1055-62.

60

Itzhaki S, Dorchin H, Clark G, Lavie L, Lavie P and Pillar G (2007). The effects of 1year treatment with a herbst mandibular advancement splint on obstructive sleep apnea, oxidative
stress, and endothelial function. Chest 131: 740-749.
Johns MW (1992). Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep
15: 376-81.
Kiely JL, Nolan P and McNicholas WT (2004). Intranasal corticosteroid therapy for
obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 59: 50-5.
Kokturk O, Ciftci TU, Mollarecep E and Ciftci B (2005). Elevated C-reactive protein
levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int
Heart J 46: 801-9.
Kraiczi H, Hedner J, Dahlof P, Ejnell H and Carlson J (1999). Effect of serotonin uptake
inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 22:
61-7.
Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry
JN, Getsy JE and Dinges DF (1993). Objective measurement of patterns of nasal CPAP use by
patients with obstructive sleep apnea. Am Rev Respir Dis 147: 887-95.
Kunisaki KM, Khalil W, Koffel E, Pfannes L, Koeller E, MacDonald R, Greer N and
Wilt TJ (2016). The Comparative Effectiveness, Harms, and Cost of Care Models for the
Evaluation and Treatment of Obstructive Sleep Apnea (OSA): A Systematic Review. Washington
(DC).
Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D, Coleman J, Jr.,
Friedman L, Hirshkowitz M, Kapen S, Kramer M, Lee-Chiong T, Owens J, Pancer JP and
American Academy of S (2006). Practice parameters for the treatment of snoring and Obstructive
Sleep Apnea with oral appliances: an update for 2005. Sleep 29: 240-3.

61

Lavie P, Fischel N, Zomer J and Eliaschar I (1983). The effects of partial and complete
mechanical occlusion of the nasal passages on sleep structure and breathing in sleep. Acta
Otolaryngol 95: 161-6.
Lebret M, Arnol N, Martinot JB, Lambert L, Tamisier R, Pepin JL and Borel JC (2017).
Determinants of Unintentional Leaks During CPAP Treatment in OSA. Chest.
Lee CH, Kim JW, Lee HJ, Yun PY, Kim DY, Seo BS, Yoon IY and Mo JH (2009). An
investigation of upper airway changes associated with mandibular advancement device using
sleep videofluoroscopy in patients with obstructive sleep apnea. Arch Otolaryngol Head Neck
Surg 135: 910-4.
Lee W, Nagubadi S, Kryger MH and Mokhlesi B (2008). Epidemiology of Obstructive
Sleep Apnea: a Population-based Perspective. Expert Rev Respir Med 2: 349-364.
Leinum CJ, Dopp JM and Morgan BJ (2009). Sleep-disordered breathing and obesity:
pathophysiology, complications, and treatment. Nutr Clin Pract 24: 675-87.
Lettieri CJ, Paolino N, Eliasson AH, Shah AA and Holley AB (2011). Comparison of
adjustable and fixed oral appliances for the treatment of obstructive sleep apnea. J Clin Sleep Med
7: 439-45.
Lewis KE, Seale L, Bartle IE, Watkins AJ and Ebden P (2004). Early predictors of CPAP
use for the treatment of obstructive sleep apnea. Sleep 27: 134-8.
Li KK, Powell NB, Riley RW, Troell RJ and Guilleminault C (2000). Long-Term Results
of Maxillomandibular Advancement Surgery. Sleep Breath 4: 137-140.
Marshall NS, Yee BJ, Desai AV, Buchanan PR, Wong KK, Crompton R, Melehan KL,
Zack N, Rao SG, Gendreau RM, Kranzler J and Grunstein RR (2008). Two randomized placebocontrolled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of
obstructive sleep apnea. Sleep 31: 824-31.

62

Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J,
Redline S and Sleep Heart Health S (2006). Association of nocturnal arrhythmias with sleepdisordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 173: 910-6.
Mehta A, Qian J, Petocz P, Darendeliler MA and Cistulli PA (2001). A randomized,
controlled study of a mandibular advancement splint for obstructive sleep apnea. Am J Respir
Crit Care Med 163: 1457-61.
Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M and Adachi
M (2004). Elevated production of tumor necrosis factor-alpha by monocytes in patients with
obstructive sleep apnea syndrome. Chest 126: 1473-9.
Morgenthaler TI, Aurora RN, Brown T, Zak R, Alessi C, Boehlecke B, Chesson AL, Jr.,
Friedman L, Kapur V, Maganti R, Owens J, Pancer J, Swick TJ, Standards of Practice Committee
of the A and American Academy of Sleep M (2008). Practice parameters for the use of
autotitrating continuous positive airway pressure devices for titrating pressures and treating adult
patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of
Sleep Medicine report. Sleep 31: 141-7.
Neruntarat C (2011). Uvulopalatal flap for obstructive sleep apnea: short-term and longterm results. Laryngoscope 121: 683-7.
Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T and Ouchi Y (2003). Effects of
obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol (1985) 94: 17984.
Oliven A, Tov N, Geitini L, Steinfeld U, Oliven R, Schwartz AR and Odeh M (2007).
Effect of genioglossus contraction on pharyngeal lumen and airflow in sleep apnoea patients. Eur
Respir J 30: 748-58.
Panossian L and Daley J (2013). Sleep-disordered breathing. Continuum (Minneap Minn)
19: 86-103.

63

Peppard PE, Young T, Barnet JH, Palta M, Hagen EW and Hla KM (2013). Increased
prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177: 1006-14.
Peppard PE, Young T, Palta M, Dempsey J and Skatrud J (2000). Longitudinal study of
moderate weight change and sleep-disordered breathing. JAMA 284: 3015-21.
Pereira EJ, Driver HS, Stewart SC and Fitzpatrick MF (2013). Comparing a combination
of validated questionnaires and level III portable monitor with polysomnography to diagnose and
exclude sleep apnea. J Clin Sleep Med 9: 1259-66.
Phillips B, Gozal D and Malhotra A (2015). What Is the Future of Sleep Medicine in the
United States? Am J Respir Crit Care Med 192: 915-7.
Powell N, Riley R, Guilleminault C and Troell R (1996). A reversible uvulopalatal flap
for snoring and sleep apnea syndrome. Sleep 19: 593-9.
Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE and Sleep Heart
Health Study I (2004). Sleep-disordered breathing, glucose intolerance, and insulin resistance: the
Sleep Heart Health Study. Am J Epidemiol 160: 521-30.
Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM and Chervin RD
(2015). Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring
with Oral Appliance Therapy: An Update for 2015. J Clin Sleep Med 11: 773-827.
Randerath WJ, Verbraecken J, Andreas S, Bettega G, Boudewyns A, Hamans E, Jalbert
F, Paoli JR, Sanner B, Smith I, Stuck BA, Lacassagne L, Marklund M, Maurer JT, Pepin JL,
Valipour A, Verse T, Fietze I and European Respiratory Society task force on non Ctisa (2011).
Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J 37: 1000-28.
Riley RW, Powell NB and Guilleminault C (1989). Maxillofacial surgery and obstructive
sleep apnea: a review of 80 patients. Otolaryngol Head Neck Surg 101: 353-61.
Rotenberg BW, Murariu D and Pang KP (2016). Trends in CPAP adherence over twenty
years of data collection: a flattened curve. J Otolaryngol Head Neck Surg 45: 43.

64

Ryan S, Taylor CT and McNicholas WT (2005). Selective activation of inflammatory
pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112: 2660-7.
Schmidt-Nowara W, Lowe A, Wiegand L, Cartwright R, Perez-Guerra F and Menn S
(1995). Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Sleep
18: 501-10.
Schwab RJ, Badr SM, Epstein LJ, Gay PC, Gozal D, Kohler M, Levy P, Malhotra A,
Phillips BA, Rosen IM, Strohl KP, Strollo PJ, Weaver EM, Weaver TE and Systems ATSSoCAT
(2013). An official American Thoracic Society statement: continuous positive airway pressure
adherence tracking systems. The optimal monitoring strategies and outcome measures in adults.
Am J Respir Crit Care Med 188: 613-20.
Schwartz AR, Bennett ML, Smith PL, De Backer W, Hedner J, Boudewyns A, Van de
Heyning P, Ejnell H, Hochban W, Knaack L, Podszus T, Penzel T, Peter JH, Goding GS,
Erickson DJ, Testerman R, Ottenhoff F and Eisele DW (2001). Therapeutic electrical stimulation
of the hypoglossal nerve in obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 127:
1216-23.
Schwartz M, Acosta L, Hung YL, Padilla M and Enciso R (2017). Effects of CPAP and
mandibular advancement device treatment in obstructive sleep apnea patients: a systematic
review and meta-analysis. Sleep Breath.
Schwengel DA, Dalesio NM and Stierer TL (2014). Pediatric obstructive sleep apnea.
Anesthesiol Clin 32: 237-61.
Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, Hamilton
GS and Dharmage SC (2017). Prevalence of obstructive sleep apnea in the general population: A
systematic review. Sleep Med Rev 34: 70-81.
Serra-Torres S, Bellot-Arcis C, Montiel-Company JM, Marco-Algarra J and AlmerichSilla JM (2016). Effectiveness of mandibular advancement appliances in treating obstructive
sleep apnea syndrome: A systematic review. Laryngoscope 126: 507-14.

65

Sharma SK, Vasudev C, Sinha S, Banga A, Pandey RM and Handa KK (2006).
Validation of the modified Berlin questionnaire to identify patients at risk for the obstructive
sleep apnoea syndrome. Indian J Med Res 124: 281-90.
Shaya FT, Lin PJ, Aljawadi MH and Scharf SM (2009). Elevated economic burden in
obstructive lung disease patients with concomitant sleep apnea syndrome. Sleep Breath 13: 31723.
Sher AE (2002). Upper airway surgery for obstructive sleep apnea. Sleep Med Rev 6:
195-212.
Shete CS and Bhad WA (2017). Three-dimensional upper airway changes with
mandibular advancement device in patients with obstructive sleep apnea. Am J Orthod
Dentofacial Orthop 151: 941-948.
Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras
JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M and Young T (2008). Sleep apnea and
cardiovascular disease: an American Heart Association/American College of Cardiology
Foundation Scientific Statement from the American Heart Association Council for High Blood
Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke
Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 52: 686-717.
Spicuzza L, Caruso D and Di Maria G (2015). Obstructive sleep apnoea syndrome and its
management. Ther Adv Chronic Dis 6: 273-85.
Stansbury RC and Strollo PJ (2015). Clinical manifestations of sleep apnea. J Thorac Dis
7: E298-310.
Strollo PJ, Jr., Soose RJ, Maurer JT, de Vries N, Cornelius J, Froymovich O, Hanson RD,
Padhya TA, Steward DL, Gillespie MB, Woodson BT, Van de Heyning PH, Goetting MG,
Vanderveken OM, Feldman N, Knaack L, Strohl KP and Group ST (2014). Upper-airway
stimulation for obstructive sleep apnea. N Engl J Med 370: 139-49.

66

Tan YK, L'Estrange PR, Luo YM, Smith C, Grant HR, Simonds AK, Spiro SG and
Battagel JM (2002). Mandibular advancement splints and continuous positive airway pressure in
patients with obstructive sleep apnoea: a randomized cross-over trial. Eur J Orthod 24: 239-49.
Teo M, Amis T, Lee S, Falland K, Lambert S and Wheatley J (2011). Equivalence of
nasal and oronasal masks during initial CPAP titration for obstructive sleep apnea syndrome.
Sleep 34: 951-5.
Thorpy MJ (2012). Classification of sleep disorders. Neurotherapeutics 9: 687-701.
Ulander M, Johansson MS, Ewaldh AE, Svanborg E and Brostrom A (2014). Side effects
to continuous positive airway pressure treatment for obstructive sleep apnoea: changes over time
and association to adherence. Sleep Breath 18: 799-807.
Valentin A, Subramanian S, Quan SF, Berry RB and Parthasarathy S (2011). Air leak is
associated with poor adherence to autoPAP therapy. Sleep 34: 801-6.
Vanderveken OM, Devolder A, Marklund M, Boudewyns AN, Braem MJ, Okkerse W,
Verbraecken JA, Franklin KA, De Backer WA and Van de Heyning PH (2008). Comparison of a
custom-made and a thermoplastic oral appliance for the treatment of mild sleep apnea. Am J
Respir Crit Care Med 178: 197-202.
Vennelle M, White S, Riha RL, Mackay TW, Engleman HM and Douglas NJ (2010).
Randomized controlled trial of variable-pressure versus fixed-pressure continuous positive airway
pressure (CPAP) treatment for patients with obstructive sleep apnea/hypopnea syndrome
(OSAHS). Sleep 33: 267-71.
Waite PD, Wooten V, Lachner J and Guyette RF (1989). Maxillomandibular
advancement surgery in 23 patients with obstructive sleep apnea syndrome. J Oral Maxillofac
Surg 47: 1256-61; discussion 1262.
Walker-Engstrom ML, Tegelberg A, Wilhelmsson B and Ringqvist I (2002). 4-year
follow-up of treatment with dental appliance or uvulopalatopharyngoplasty in patients with
obstructive sleep apnea: a randomized study. Chest 121: 739-46.

67

Whyte KF, Gould GA, Airlie MA, Shapiro CM and Douglas NJ (1988). Role of
protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep 11: 463-72.
Won CH, Li KK and Guilleminault C (2008). Surgical treatment of obstructive sleep
apnea: upper airway and maxillomandibular surgery. Proc Am Thorac Soc 5: 193-9.
Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T and
Adachi M (2003). Elevated levels of C-reactive protein and interleukin-6 in patients with
obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.
Circulation 107: 1129-34.
Yucel A, Unlu M, Haktanir A, Acar M and Fidan F (2005). Evaluation of the upper
airway cross-sectional area changes in different degrees of severity of obstructive sleep apnea
syndrome: cephalometric and dynamic CT study. AJNR Am J Neuroradiol 26: 2624-9.
Zhu X, Wimms AJ and Benjafield AV (2013). Assessment of the performance of nasal
pillows at high CPAP pressures. J Clin Sleep Med 9: 873-7.

68

APPENDIX A: EXPERIMENTAL DATA

69

Appendix A: Experimental Data

Name

Age

M/F

ESS Score
Before

ESS Score
After

ESS Difference

Subject 1

56.9 F

12

9

-3

Subject 2

73.7 F

5

4

-1

Subject 3

72.3 M

12

13

1

Subject 4

69 F

3

1

-2

Subject 5

67.1 F

16

17

1

Subject 6

71.6 F

6

5

-1

Subject 7

65 F

8

7

-1

Subject 8

46.3 M

4

2

-2

Subject 9

60.5 M

9

9

0

58 M

4

1

-3

7

8

1

8

2

-6

5

3

-2

Subject 10
Subject 11
Subject 12
Subject 13

65.3 F
49 M
45.9 F
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Appendix A: Experimental Data

Name

AHI
Before

AHI
After

AHI
Difference

Pressure
Before

Pressure
After

Pressure
Change

Subject 1

2.6

1.3

-1.3

13.8

11.3

-2.5

Subject 2

1

1

0

16

17.9

1.9

Subject 3

3.8

9.9

6.1

11

11.4

0.4

Subject 4

1

0.9

-0.1

12.7

13.6

0.9

Subject 5

0.6

0.5

-0.1

10.2

11.9

1.7

Subject 6

1.7

1.1

-0.6

14.3

14.1

-0.2

Subject 7

3.6

3.7

0.1

14.4

12.5

-1.9

Subject 8

4.6

1.3

-3.3

13.9

13.6

-0.3

Subject 9

0.4

0.2

-0.2

9

9.1

0.1

Subject 10

1.6

0.9

-0.7

11.3

9.7

-1.6

Subject 11

2.3

2.2

-0.1

12.7

14

1.3

Subject 12

2.7

1.3

-1.4

11.6

8.3

-3.3

Subject 13

0.9

1.6

0.7

10.3

11.4

1.1
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Appendix A: Experimental Data

Name

Compliance Compliance Compliance Leaks
Before
After
Change
Before

Leaks
After

Leak
Change

Subject 1

9%

97%

88%

29.9

26.6

-3.3

Subject 2

31%

27%

-4%

24.7

9.7

-15

Subject 3

44%

40%

-4%

4.1

3.5

-0.6

Subject 4

63%

97%

34%

3.5

5

1.5

Subject 5

46%

63%

17%

3.6

14.4

10.8

Subject 6

60%

50%

-10%

27.3

45.3

18

Subject 7

61%

63%

2%

31.1

11.6

-19.5

Subject 8

58%

97%

39%

5.3

4.3

-1

Subject 9

29%

87%

58%

20.4

18

-2.4

Subject 10

29%

77%

48%

16.7

17.7

1

Subject 11

61%

61%

0%

12.7

7.2

-5.5

Subject 12

27%

30%

3%

2.7

3.1

0.4

Subject 13

58%

87%

29%

15.8

20.3

4.5
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t-Test: Paired Two Sample for Means
Variable

Mean

95% CI for
Mean

Standard
Deviation

Standard
Error

p-value

Pressure
Before

12.4

(11.1717,
13.6283)

2.0327

0.5638

Pressure
After

12.2154

(10.6887,
13.7421)

2.5265

0.7007

Pressure
After –
Pressure
Before

-0.1846

(-1.1924,
0.8232)

1.6678

0.4626

0.6968

95% CI for
Mean
(34.5375,
54.0779)
(53.3762,
81.3930)

Standard
Deviation
17.6134

Standard
Error
4.8851

p-value

25.2538

7.0042

(5.2520,
40.901)

29.4971

8.1810

t-Test: Paired Two Sample for Means
Variable

Mean

Compliance
Before
Compliance
After

44.3077

Compliance
After –
Compliance
Before

23.0769

67.3846

0.0154
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t-Test: Paired Two Sample for Means
Variable

Mean

ESS Score
Before
ESS Score
After
ESS Score
After – ESS
Score Before

7.6154
6.2308
-1.3846

95% CI for
Mean
(5.3072,
9.9236)
(3.2688,
9.1928)
(-2.5815, 0.1877)

Standard
Deviation
3.8197

Standard
Error
1.0594

p-value

4.9016

1.3595

1.9807

0.5493

0.0269

p-value

t-Test: Paired Two Sample for Means
Variable

Mean

95% CI for
Mean

Standard
Deviation

Standard
Error

AHI Before

2.0615

1.3364

0.3706

AHI After

1.9923

2.5280

0.7011

AHI After –
AHI Before

-0.0692

(1.2540,
2.8691)
(0.4647,
3.5200)
(-1.3405,
1.2020)

2.1037

0.5835

0.9075
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t-Test: Paired Two Sample for Means
Variable

Mean

95% CI for
Mean

Standard
Deviation

Standard
Error

Leaks Before

15.2154

(8.7107,
21.7200)

10.7640

2.9854

Leaks During

14.3615

11.8354

3.2826

Leaks During –
Leaks Before

-0.8538

(7.2095,
21.5136)
(-6.6614,
4.9537)

9.6105

2.6655

p-value

0.7542

Comparing Male Vs Female
Gender
M

Change in Air
Pressure
-0.94

Change in
Compliance
29%

Change in
ESS
-2

Change in
AHI
0.1

Change in
Leaks
0.52

F

0.2875

20%

-1

-0.175

-1.0625

0.8289

0.1231

0.0002

0.0006

0.6024

0.3992

0.8718

0.9067

Statistical
Test
f-Test p- 0.9133
value
t-Test p- 0.2100
value

